Basic and clinical studies were made on KW-1062, a new aminoglycoside antibiotic developed by Kyowa Hakko Kogyo Co. The results obtained were as follows :
1) The MICs of KW-1062 against 46 strains of Pseudomonas aeruginosa were between 1.6 and 12.5 μg/ml, and those against 17 strains of Proteus mirabilis were between 0.4 and 6.2 μg/ml.
2) Intramuscular injection of 40 mg KW-1062 yielded a peak blood level up to 7.0 μg/ml in half an hour, the urinary recovery being 68.8% of the dosage in 8 hours; while only 0.26% was recovered from the bile in two hours.
3) Distribution of the KW-1062 into rats organs : The highest tissue concentration of the antibiotic was found in kidney, followed by serum, lung, spleen, and liver. The distribution pattern was similar to those found in other aminoglycosides.
4) Twelve clinical cases (urinary tract infections 6, respiratory tract infections 6) were treated with KW-1062 at a dosis of 80 mg-120 mg (i. m.) per day. Six cases responded well to the treatment.
Side effects were found in three of the cases, i. e. slight elevation of S-GOT and S-GPT, microhaematuria, and a slight drop of respiration rate in amyasthenia gravis case ;all of those adverse reaction & disappeared soon after cessation of dosing.
